KYNB · Kyntra Bio, Inc.
$7.07
-0.15 (-2.01%)
At close · Jul 23
Market Cap
$28.46M
Shares
4.05M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$6.44M
-78.3%
FY2025
Net Income
$183.45M
+485.6%
FY2025
Gross Margin
91.37%
+43.9pp
FY2025
Operating Margin
-712.66%
-204.9pp
FY2025
Diluted EPS
$45.37
+481.6%
FY2025
Operating Cash Flow
-$4.77M
+96.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.44M | $6.44M | $29.62M | $46.8M | $140.73M | $235.31M | $176.32M | $256.58M | $212.96M | $131M | $183.19M | $180.83M | $137.6M | $102.17M | |
| $4.41M | $556K | $15.56M | $3.96M | $20.28M | $12.87M | $8.87M | $1.15M | — | — | — | — | — | — | |
| $3.03M | $5.88M | $14.06M | $42.84M | $120.45M | $222.44M | $167.45M | $255.43M | — | — | — | — | — | — | |
| — | 91.37% | 47.47% | 91.53% | 85.59% | 94.53% | 94.97% | 99.55% | — | — | — | — | — | — | |
| $21.91M | $23.52M | $95.69M | $266.47M | $296.79M | $387.04M | $252.92M | $209.27M | $235.84M | $196.52M | $187.21M | $214.09M | $150.79M | $85.71M | |
| — | — | — | — | — | — | — | — | $63.81M | $51.76M | $46.03M | $44.36M | $36.91M | $24.41M | |
| $25.47M | $27.71M | $49.33M | $86.48M | $124.69M | $123.93M | $106.41M | $135.48M | $63.81M | $51.76M | — | — | — | — | |
| $449K | $553K | $19.45M | $12.61M | $0 | $0 | — | — | — | — | — | — | — | — | |
| $401.75M | — | — | — | — | — | $368.2M | $345.89M | $299.65M | $248.28M | $233.23M | $258.45M | $187.7M | $110.12M | |
| $52.23M | $52.34M | $180.04M | $369.52M | $441.76M | $523.84M | $368.2M | $345.89M | — | — | — | — | — | — | |
| -$44.79M | -$45.9M | -$150.42M | -$322.72M | -$301.03M | -$288.53M | -$191.88M | -$89.31M | -$86.69M | -$117.28M | -$50.04M | -$77.63M | -$50.1M | -$7.95M | |
| — | -712.66% | -507.8% | -689.53% | -213.9% | -122.62% | -108.83% | -34.81% | -40.71% | -89.53% | -27.32% | -42.93% | -36.41% | -7.78% | |
| $8.93M | $8.76M | $8.25M | $8.1M | $1.44M | $1.08M | $2.4M | $2.88M | $10.99M | $9.71M | $10.73M | $11.03M | $11.11M | $10.7M | |
| $3.64M | $2.94M | $5.3M | $7.59M | $7.6M | -$1.08M | $5.55M | $15.55M | — | — | — | — | — | — | |
| $3.28M | — | — | $2.64M | $1.57M | $1.01M | -$202K | $0 | — | — | — | — | — | — | |
| -$56.66M | -$58.29M | -$153.37M | -$323.22M | -$294.87M | -$290.68M | -$188.73M | -$76.64M | -$86.12M | -$120.55M | -$58.14M | -$85.54M | -$59.5M | -$14.94M | |
| -$92K | -$90K | -$269K | -$252K | $358K | $347K | $360K | $328K | $304K | $321K | -$71K | $242K | $0 | $0 | |
| $163.62M | $183.45M | -$47.58M | -$284.23M | -$293.65M | -$290.02M | -$189.29M | -$76.97M | -$86.42M | -$120.88M | -$58.07M | -$85.78M | -$59.5M | -$14.94M | |
| — | 2848.63% | -160.63% | -607.29% | -208.66% | -123.25% | -107.36% | -30% | -40.58% | -92.27% | -31.7% | -47.44% | -43.24% | -14.63% | |
| $166.16M | $187M | -$46.44M | -$285.39M | -$295.21M | -$289.69M | -$193.04M | -$76.05M | -$85.66M | -$121.71M | -$57.38M | -$84.28M | -$59.15M | -$18.28M | |
| USD/shares | — | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | — | — | — | — | — | — | — |
| USD/shares | — | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | — | — | — | — | — | — | — |
| shares | — | 4.04M | 4M | 3.89M | 3.74M | 3.69M | 3.59M | 3.47M | 3.36M | 2.92M | 2.51M | 2.41M | 751K | 527.44K |
| shares | — | 4.04M | 4M | 3.89M | 3.74M | 3.69M | 3.59M | 3.47M | 3.36M | 2.92M | 2.51M | 2.41M | 751K | 527.44K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
0.17×
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Europe | $5,643,000 | $6,270,000 | $9,549,000 | $33,820,000 | $131,243,000 | $17,954,000 | $145,641,000 | $112,916,000 |
| Japan | $797,000 | -$2,854,000 | $15,867,000 | $9,764,000 | $2,305,000 | $19,824,000 | -$23,167,000 | $100,002,000 |
| China | $0 | $91,000 | $8,426,000 | $84,631,000 | $55,640,000 | $73,361,000 | $20,967,000 | $0 |
| United States | $0 | $26,114,000 | $12,961,000 | $12,519,000 | $46,121,000 | $65,180,000 | $113,134,000 | — |
| All Other | — | — | — | — | — | — | $2,000 | $40,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Drug Product Revenue | $5,848,000 | $27,673,000 | — | — | — | — | — | — |
| Development and Other Revenue | $592,000 | $1,948,000 | — | — | — | — | — | — |
| Development and Other Revenue | — | — | $18,401,000 | $24,189,000 | $70,275,000 | $80,592,000 | $114,115,000 | $125,913,000 |
| Drug Product Revenue | — | — | $18,753,000 | $11,086,000 | $962,000 | $8,906,000 | -$36,324,000 | $64,776,000 |
| License | — | — | $9,649,000 | $22,590,000 | $116,434,000 | $14,323,000 | $177,086,000 | $22,269,000 |
| Product | — | — | — | $82,869,000 | $47,638,000 | $72,498,000 | $1,700,000 | $0 |